YouTube Facebook LinkedIn Google+ Twitter Xingrss  



August 13, 2003 | The Mirus Genomic Index, prepared exclusively for Bio·IT World, is calculated as the sum of the market capitalizations of all included companies and is consequently a value-weighted index. It serves as an indicator of the financial health of the industry. The index was developed at RCW Mirus (www.merger.com), an investment banking firm, by David Hoffer and colleagues at the firm's Boston headquarters.

Discovery Companies
Company3 Market
Cap1 
Revenues
TTM2 
Net Income
TTM2 
Celera Genomics (CRA) 756.7 94.9  (91.3)
CuraGen Corp. (CRGN) 262.4 15.4  (86.9)
deCODE Genetics Inc. (DCGN) 170.7 47.6  (129.1)
DNAPrint Genomics (DNAP.OB) 40.4 0.2  (3.2)
Exelixis Inc. (EXEL) 426.5 45.1  (90.7)
Genome Therapeutics Corp. (GENE) 63.8 19.5  (36.0)
Human Genome Sciences (HGSI) 1621.5 4.6  (222.7)
Nuvelo (NUVO)4 115.3 22.5  (39.6)
Incyte Genomics Inc. (INCY) 339.1 85.1  (179.2)
Interleukin Genetics Inc. (ILGN) 12.9 0.3  (5.5)
Lexicon Genetics Inc. (LEXG) 343.9 35.6  (62.8)
Millennium Pharmaceuticals (MLNM) 4646.6 366.2  (424.2)
Myriad Genetics Inc. (MYGN) 383.9 62.7  (24.5)
Rigel Pharmaceuticals Inc. (RIGL) 47.3 16.2  (36.4)
Sequenom Inc. (SQNM) 108.0 29.6  (85.9)
Vertex Pharmaceuticals (VRTX) 1174.3 143.0  (135.22)5
Q2 2003 Index = 10,513

Tools Companies
Company3 Market
Cap1 
Revenues
TTM2 
Net Income
TTM2 
Aclara Biosciences (ACLA) 145.2 2.1 (34.4)
Affymetrix Inc. (AFFX) 1141.9 288.6 (10.8)
Applied Biosystems Group (ABI) 3950.1 1667.0 141.6 
Ciphergen Biosystems (CIPH) 272.1 45.3 (31.1)
Compugen Ltd. (CGEN) 127.4 10.9 (11.3)
Epoch Biosciences Inc. (EBIO) 68.6 11.4 (2.9)
Harvard Bioscience Inc. (HBIO) 114.0 64.9 0.7 
Illumina Inc. (ILMN) 93.8 13.1 (40.6)
Invitrogen Corp. (IVGN) 1964.9 669.3 50.1 
LION bioscience AG (ADR) (LEON) 89.6 31.9 (163.6)
Luminex Corp. (LMNX) 156.0 15.9 (18.8)
Qiagen N.V. (QGENF) 1204.1 307.4 24.7 
Third Wave Technologies (TWTI) 191.7 30.7 (36.4)
Transgenomic Inc. (TBIO) 47.9 37.2 (21.6)
Varian Inc. (VARI) 1143.1 806.7 54.1 
Q2 2003 Index = 10,710

1) Market cap is the number of shares outstanding x share price as of June 30, 2003 (in $ millions).

2) TTM is trailing 12 months ending March 31, 2003, for all companies (all financials in $ millions).

3) Deltagen filed for Chapter 11 on June 27 and has been removed from the index pending emergence from bankruptcy. Oxford Glycosciences was acquired by CellTech in April of 2003 and has been removed from the index.

4) Hyseq has been replaced with Nuvelo, the new company formed through the merger of Hyseq and VariaGenics in February of 2003.

5) Vertex Pharmaceuticals' net income for Q1 2003 has been adjusted for a one-time $69-million gain from disposal of assets.

RCW Mirus Inc. does not assume any liability for errors or omissions.

Back to Discovery Surges and Tools Deliver in Q2 



For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.